Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $121.5752W HIGH $170.46
Volume
1.90 M
Value Traded
155.65 M
Short % Float
0.28%
+1.95%Week
+4.56%1 Month
-6.69%3 Month
-6.69%6 Month
+82.32%5 Year
+866.4%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
292.51 B
EPS (TTM)
7.06
P/E Ratio
20.36
Ent. Value
318.17 B
Total Shares
2.03 B
Float Shares
1.83 B
Insiders
0.01%
Institutions
7.47%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NVS Catalyst Timeline
Dated clinical, regulatory and corporate events for Novartis AG
Catalyst Timeline
Dated clinical, regulatory & corporate events for Novartis AG
94Total events
18Upcoming
48Tier-1 (high impact)
2024 to 2026Coverage
Upcoming catalysts 2
Event history 46
▲FDA ApprovalRhapsidoApprovedFDA Decision
FDA approves Rhapsido (remibrutinib) for symptomatic dermographism
symptomatic dermographism (SD)source ↗
▲Partnership / LicenseABO2203Corporate
Abogen enters licensing and option agreement with Novartis for ABO2203 and other RNA programs
autoimmune diseasessource ↗
▲Partnership / LicenseCorporate
CAS announces collaboration with Novartis Biomedical Research on AI-ready reaction informatics
▲Partnership / LicenseCorporate
BoomRay enters exclusive global license agreement with Novartis for undisclosed preclinical RLT asset
▲CHMP Positive OpinionCosentyxApprovedEx-US Regulatory
CHMP adopts positive opinion for Cosentyx in PMR
polymyalgia rheumatica (PMR)source ↗
▼Primary Endpoint Misseddel-desiranClinical Data
HARBOR Phase III missed primary endpoint of vHOT in DM1
myotonic dystrophy type 1 (DM1)source ↗
▲Priority Reviewdelpacibart zotadirsenFiledRegulatory Filing
FDA priority review granted for del-zota
Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44)source ↗
▲Secondary Endpoint Datadel-desiranClinical Data
Evidence of clinical activity in secondary endpoints and exploratory analyses in HARBOR
myotonic dystrophy type 1 (DM1)source ↗
●Runway Guidance UpdateCorporate
Novartis maintains 5-6% five-year sales CAGR guidance for 2025-2030
●Safety Data Updatedel-desiranClinical Data
HARBOR safety findings generally consistent with previously reported data
myotonic dystrophy type 1 (DM1)source ↗
▼Primary Endpoint MissedPelacarsenClinical Data
Lp(a)HORIZON did not meet primary endpoint of reducing cardiovascular events
elevated Lp(a) and established cardiovascular diseasesource ↗
▲Partnership / LicenseALT-B4Corporate
Alteogen enters option and license agreement with Novartis for ALT-B4 subcutaneous products
▲Primary Endpoint MetRemibrutinibApprovedClinical Data
REMODEL-1/-2 met primary endpoint reducing annualized relapse rate vs teriflunomide
relapsing multiple sclerosissource ↗
▲FDA ApprovalFabhaltaApprovedFDA Decision
FDA traditional approval for Fabhalta to slow kidney function decline in primary IgAN
primary immunoglobulin A nephropathy (IgAN)source ↗
▲Full ResultsFabhaltaApprovedClinical Data
Phase III APPLAUSE-IgAN results supporting traditional approval
primary immunoglobulin A nephropathy (IgAN)source ↗
▲Partnership / LicenseCorporate
Chai Discovery announces collaboration with Novartis to advance AI-driven antibody discovery
▲Partnership / LicenseCorporate
Acquisition of Myricx Bio with NMTi ADC payload platform and two lead assets (B7-H3 and HER2)
solid tumorssource ↗
▲FDA ApprovalFabhaltaApprovedFDA Decision
FDA traditional approval of Fabhalta for IgAN
primary immunoglobulin A nephropathy (IgAN)source ↗
▲EU ApprovalItvismaApprovedEx-US Regulatory
European Commission approval for Itvisma for SMA in children ≥2 years, teens, and adults
spinal muscular atrophy (SMA)source ↗
●Oral PresentationCosentyxApprovedPresentation
REPLENISH data presented at EULAR 2026 Congress
polymyalgia rheumatica (PMR)source ↗
▲EU ApprovalRhapsidoApprovedEx-US Regulatory
EC approval of Rhapsido for CSU
chronic spontaneous urticaria (CSU)source ↗
▲EU ApprovalItvismaApprovedEx-US Regulatory
EC approval of Itvisma for broad SMA population
5q spinal muscular atrophy (SMA)source ↗
▲Pediatric Exclusivity GrantedKisqaliApprovedFDA Decision
FDA granted pediatric exclusivity for Kisqali
early breast cancer (eBC)source ↗
●BLA Submissiondel-zotaFiledRegulatory Filing
BLA submitted to FDA for accelerated approval of del-zota in DMD
Duchenne muscular dystrophy (DMD) amenable to exon 44 skippingsource ↗
▲Biomarker Datadel-braxClinical Data
Positive Phase I/II biomarker data for del-brax in FSHD
facioscapulohumeral muscular dystrophy (FSHD)source ↗
▲Primary Endpoint MetRhapsidoApprovedClinical Data
Phase III RemIND study met primary endpoint in CIndU
chronic inducible urticaria (CIndU)source ↗
▲Full ResultsRhapsidoApprovedClinical Data
Phase IIIb REMIXED extension study results in CSU presented at EAACI
chronic spontaneous urticaria (CSU)source ↗
▲Subgroup AnalysisPluvictoApprovedClinical Data
Subgroup analyses from PSMAddition study of Pluvicto in mHSPC presented at ASCO
metastatic hormone-sensitive prostate cancer (mHSPC)source ↗
▲Full ResultsCosentyxApprovedClinical Data
Phase III REPLENISH study results in PMR published in NEJM and presented at EULAR
polymyalgia rheumatica (PMR)source ↗
▲Full ResultsIanalumabClinical Data
Phase III NEPTUNUS studies of ianalumab in Sjögren's Disease
Sjögren's Diseasesource ↗
●NDA SubmissionVanrafiaApprovedRegulatory Filing
Regulatory submissions for Vanrafia in IgAN completed in US and EU
IgANsource ↗
▲WHO PrequalificationCoartemApprovedEx-US Regulatory
WHO prequalification of Coartem Baby for newborns and young infants
malariasource ↗
●Oral PresentationRhapsidoApprovedPresentation
Phase III CIndU data presented at EAACI
chronic inducible urticaria (CIndU)source ↗
▲Oral PresentationPluvictoApprovedPresentation
PSMAddition PSA response data presented at AUA
metastatic hormone-sensitive prostate cancer (mHSPC)source ↗
▲Primary Endpoint MetCosentyxApprovedClinical Data
Phase III REPLENISH met primary endpoint in PMR
polymyalgia rheumatica (PMR)source ↗
●Oral PresentationCosentyxApprovedPresentation
REPLENISH data presented at EULAR
polymyalgia rheumatica (PMR)source ↗
▲Full ResultsIanalumabClinical Data
Phase III NEPTUNUS studies of ianalumab in Sjögren's Disease
Sjögren's Diseasesource ↗
▲Other Regulator MilestoneRhapsidoApprovedEx-US Regulatory
Japan MHLW approval of Rhapsido for CSU
chronic spontaneous urticaria (CSU)source ↗
▲Additional DataPluvictoApprovedClinical Data
PSMAddition PSA response data presented at AUA
mHSPCsource ↗
▲Priority ReviewFabhaltaApprovedRegulatory Filing
Priority review designation for Fabhalta in IgAN
primary immunoglobulin A nephropathy (IgAN)source ↗
▲Full ResultsFabhaltaApprovedClinical Data
Phase III APPLAUSE-IgAN study results supporting approval
primary immunoglobulin A nephropathy (IgAN)source ↗
▲Accelerated ApprovalFabhaltaApprovedFDA Decision
Initial FDA accelerated approval for reduction of proteinuria in primary IgAN
primary immunoglobulin A nephropathy (IgAN)source ↗
Past FDA Catalysts and PDUFA Decisions
How NVS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-31 | Pluvicto (lutetium lu-177 vipivotide tetraxetan) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A80 / 100
Pipeline Score
$63.0B
Pipeline Value
$232.2B
Commercial Value
Fair Value
Valuation Signal
175
Drugs Scored
0.7x
rNPV / MCap
Top 2%
Large Pharma(rank 14 of 658)
Percentile Rank
Novartis AG earns an A-grade pipeline score (80/100), with $63.1B risk-adjusted pipeline value, led by Iscalimab in Type 1 Diabetes Mellitus (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K)) Revenue $54.8B x 4.2 = $232.2B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Cosentyx | $6.9B | $6.5B | +6.9% |
| Kisqali | $5.9B | $3.8B | +53.3% |
| Entresto | $5.6B | $8.7B | -35.2% |
| Kesimpta | $5.0B | $3.8B | +33.8% |
| Pluvicto | $2.5B | $1.6B | +57.6% |
| Jakavi | $2.2B | $2.0B | +11.2% |
| Tafinlar + Mekinist | $2.2B | $2.2B | -1% |
| Ilaris | $2.0B | $1.7B | +19.7% |
| Scemblix | $1.7B | $925M | +88.5% |
| Leqvio | $1.6B | $976M | +61.4% |
| Xolair | $1.6B | $1.7B | -9.4% |
| Zolgensma Group | $1.3B | $1.2B | +6.8% |
Top 12 of 25 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Iscalimab Monoclonal antibodyCompletedNCT04129528 | Type 1 Diabetes Mellitus | Phase 2 | COMPLETED | 44 | Jun 4, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every NVS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| del-desiran BreakthroughFast TrackOrphan | myotonic dystrophy type 1 (DM1) | Phase 3 | 2026-09-08 | did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT)Read More | Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NVS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.2 % (-33.3 %) | 31.34 M | 200.00 K | -20% ( -50.00 K) |
NVS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2028-01-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NVS ranks across every disease it competes in
Competitive Position is a premium feature
See how NVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNVS News
NVS▲ +0.4%today
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
Novartis has received FDA approval for Rhapsido® (remibrutinib) as the first treatment for symptomatic dermographism (SD), providing a new option for patients inadequately controlled by H1 antihistamines. The approval is based on positive results from the Phase III RemIND trial, which showed significant improvement in hive resolution compared to placebo. This marks a significant advancement in treatment options for chronic hives.
Read more →NVS▲ +0.4%today
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Novartis is set to present late-breaking data from its Phase III REMODEL-1/-2 trials at MSToronto2026, showcasing the efficacy and safety of remibrutinib for relapsing multiple sclerosis (RMS). Additionally, new data on Kesimpta (ofatumumab) will be shared, focusing on its use in pediatric MS and other treatment scenarios. This reflects Novartis's ongoing dedication to advancing care for MS patients.
Read more →NVSAbogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
Abogen Biosciences has entered a licensing agreement with Novartis for its mRNA-encoded T-cell engager, ABO2203, aimed at treating autoimmune diseases. The deal grants Novartis exclusive rights to ABO2203 and options for other programs from Abogen's RNA platform. Abogen will receive an upfront payment of $575 million and could earn up to $7.2 billion in milestone payments. This partnership highlights the potential of mRNA technology in therapeutic applications.
Read more →NVSCAS announces collaboration with Novartis to advance AI-ready reaction informatics
CAS has announced a collaboration with Novartis Biomedical Research to enhance reaction data accessibility through AI-enabled research. This partnership will provide Novartis with an integrated platform for searching and analyzing proprietary and curated reaction data. The initiative aims to streamline drug discovery workflows and improve the efficiency of data utilization in research.
Read more →NVSCAS gibt Zusammenarbeit mit Novartis bekannt, um die KI-fähige Reaktionsinformatik voranzutreiben
CAS has announced a collaboration with Novartis Biomedical Research to improve access to reaction data and support AI-driven research. This initiative will provide Novartis researchers with a searchable platform for proprietary experimental reaction data and over 160 million curated reactions. The project aims to enhance the efficiency of accessing and analyzing reaction data across various research systems.
Read more →NVSCAS anuncia una colaboración con Novartis para impulsar la informática de reacciones preparada para la IA
CAS has announced a collaboration with Novartis Biomedical Research to enhance accessibility to reaction data and support AI-driven research. This partnership will provide Novartis researchers with integrated access to both internal experimental reaction data and over 160 million curated reactions. The initiative aims to streamline data discovery and analysis, facilitating more efficient drug discovery workflows.
Read more →NVSBoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
BoomRay Pharmaceuticals has signed an exclusive global license agreement with Novartis for a preclinical radioligand therapy asset. The deal could yield up to USD 900 million in payments and royalties, combining BoomRay's innovative capabilities with Novartis's expertise in oncology. This partnership aims to advance the development of new treatment options for patients worldwide.
Read more →NVSNovartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
Novartis has received a positive opinion from the CHMP for Cosentyx (secukinumab) as a treatment for polymyalgia rheumatica (PMR). If approved, it will be the first IL-17A inhibitor available in Europe for PMR, providing a significant alternative to steroid treatments. The recommendation is based on data from the REPLENISH Phase III trial, which demonstrated improved remission rates and safety consistent with prior studies.
Read more →NVS▼ -13.9%on this news
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Novartis announced that the Phase III HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint of video hand opening time. However, the study indicated clinical activity in secondary endpoints. Novartis is evaluating the full dataset to determine the next steps for del-desiran while continuing to advance its neuromuscular pipeline.
Read more →NVS▼ -13.9%on this newsshared move
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Novartis announced that the Phase III Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint of reducing cardiovascular events compared to placebo. While the treatment successfully lowered Lp(a) levels, it did not translate into a reduced risk of cardiovascular issues in the overall population. The results provide new insights into the relationship between Lp(a) and cardiovascular outcomes.
Read more →NVSAlteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
Alteogen has entered into a licensing agreement with Novartis to develop and commercialize subcutaneous formulations using its ALT-B4 technology. This partnership allows Novartis to explore multiple products, potentially leading to significant financial gains for Alteogen. The agreement reflects Novartis' commitment to improving patient treatment experiences through innovative solutions.
Read more →NVS▲ +6%on this newsshared move
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Novartis announced positive results from its Phase III REMODEL-1/-2 trials for remibrutinib, a BTK inhibitor, showing significant reductions in relapse rates and inflammatory brain lesions in patients with relapsing multiple sclerosis. The trials met primary and secondary endpoints, demonstrating a favorable safety profile. Novartis plans to seek global regulatory approval and present data at MSToronto2026.
Read more →NVSNovartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Novartis will present significant cardiovascular data at the 2026 ESC Congress, emphasizing its leadership in the field. Key studies include the VICTORION-CHALLENGE data on Leqvio and analyses of abelacimab's bleeding profile. The company aims to advance cardiovascular care through innovative therapies and a strong pipeline.
Read more →NVSFDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
The FDA has approved Pluvicto for patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), significantly expanding treatment options. Clinical trials showed that Pluvicto, in combination with standard care, reduced the risk of progression or death by 33%. This approval nearly doubles the eligible patient population, highlighting the need for earlier treatment intensification in this incurable disease.
Read more →NVSNovartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Novartis reported a 1% increase in net sales for Q2 2026, driven by strong performances from priority brands such as Kisqali and Leqvio. Despite a decline in net income and operating income, the company reaffirmed its full-year guidance, expecting low single-digit growth. Notable pipeline advancements include FDA submissions and approvals for new therapies.
Read more →NVSNovartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartis has received FDA traditional approval for Fabhalta (iptacopan), the first complement inhibitor to significantly slow kidney function decline in adults with primary IgAN. The approval is based on the Phase III APPLAUSE-IgAN study, which demonstrated a 48% reduction in eGFR decline compared to placebo. This milestone is expected to provide renewed hope for patients suffering from this progressive disease.
Read more →NVSChai Discovery Announces Collaboration with Novartis to Advance AI-Driven Antibody Discovery
Chai Discovery has announced a collaboration with Novartis focused on advancing AI-driven antibody discovery. This partnership aims to leverage artificial intelligence to enhance the efficiency and effectiveness of antibody development. The collaboration signifies a strategic move in the biopharma sector, potentially leading to innovative therapeutic solutions.
Read more →NVSSofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis
Sofinnova Partners has announced that Myricx Bio has agreed to be acquired by Novartis. This acquisition is expected to bolster Novartis' capabilities in the biopharmaceutical sector. The deal highlights Novartis' commitment to expanding its portfolio and enhancing its market position.
Read more →NVSMyricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
Myricx Bio has announced its acquisition by Novartis for up to $1.5 billion, including $1.1 billion in cash upfront. This acquisition aims to leverage Novartis's oncology expertise and Myricx's innovative N-myristoyltransferase inhibitor (NMTi) payload platform, which has potential applications across various solid tumors. The deal is expected to close in the second half of 2026, pending regulatory approvals.
Read more →NVSNovartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Novartis has announced its agreement to acquire Myricx Bio, a UK-based biotech company specializing in antibody-drug conjugates (ADCs) with a novel N-myristoyltransferase inhibitor (NMTi) payload. This acquisition aims to enhance Novartis' oncology pipeline and address limitations of current ADC payloads. The deal involves an upfront payment of $1.1 billion, with additional milestone payments possible, and is expected to close in the second half of 2026, pending regulatory approvals.
Read more →About Novartis AG
BIOPHARMAWATCH ELITE PLUS
Trade the next NVS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime